Bristol Myers Squibb's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bristol Myers Squibb (BMY) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bristol Myers Squibb vs Its Competitors
- TTM: Trailing 12-month revenue of 49,186M vs 577,298M combined for tracked competitors (7.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+5.5% annualized vs trailing 12 months), vs accelerating (+5.2%) for its tracked peer group.
- Growth: Bristol Myers Squibb generated 5.7% revenue growth year over year in Q2 2026, vs 11.7% for its tracked competitors combined.
- Profitability: Its 25.6% net margin compares with 3.8% for the peer group.
- Scale: Bristol Myers Squibb ranks #11 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 2.4% of industry market cap.
- Peer revenue share: Bristol Myers Squibb accounted for 7.9% of combined revenue among its tracked peer group, down from 8.3% a year earlier.
- Peer differentiation: Revenue per employee of $1.51M compares with $0.89M for the peer group (1.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BMY Sales vs. its Competitors, Q2 2026
Bristol Myers Squibb reported revenue growth of 5.74 % year on year in Q2 2026, below its competitors' combined revenue growth of 11.67 %.
With a net margin of 25.56 %, Bristol Myers Squibb achieved higher profitability than its competitors (3.79 %).
Bristol Myers Squibb generated 7.87 % of the combined sales of its peer group, down from 8.28 % a year earlier.
Bristol Myers Squibb vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Bristol Myers Squibb and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Bristol myers Squibb Company | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (49) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Bristol Myers Squibb's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 5.7% for Bristol Myers Squibb. Bristol Myers Squibb's share of combined industry revenue moved from 1.71% to 1.69%, a loss of 0.02 percentage points.
Bristol Myers Squibb's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bristol myers Squibb Company | Yes | Yes | No | No |
| Competitors combined (289) | ||||
| High-Confidence Competitors (78) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 25.00 % (2 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BMY Stock Performance relative to its Competitors
BMY Stock Performance relative to High-Confidence Competitors
BMY Stock Performance relative to Similar-Size Competitors
BMY Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Gt Biopharma Inc | 282.9% | Outperformed |
| 4 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 5 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bristol Myers Squibb's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bristol Myers Squibb's Comment on Competition and Industry Peers
Publicly Traded Peers of Bristol myers Squibb Company
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Bristol myers Squibb Company | 130,437.12 | 49,186.00 |
| Akari Therapeutics Plc | 1,180,444.71 | - |
| Eli Lilly And Company | 1,054,271.08 | 79,665.80 |
| Johnson and Johnson | 662,243.14 | 97,929.00 |
| Beone Medicines Ltd | 543,751.77 | 6,128.24 |
| Abbvie Inc | 473,290.90 | 64,386.00 |
| SUBTOTAL | 6,926,758.58 | 931,750.19 |
Sign in to see all competitors of Bristol myers Squibb Company.
Sources: Bristol myers Squibb Company's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bristol myers Squibb Company versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bristol Myers Squibb's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Named by the company | 85% |
| Shattuck Labs Inc | Named by the company | 85% |
| Protagonist Therapeutics inc | Named by the company | 85% |
| Monopar Therapeutics Inc | Named by the company | 85% |
| Cadrenal Therapeutics Inc | Named by the company | 85% |
| Agentix Corp | Named by the company | 85% |
| Spyre Therapeutics Inc | Named by the company | 85% |
| MNMD | Named by the company | 85% |
| Cabaletta Bio Inc | Named by the company | 85% |
| Exagen Inc | Named by the company | 85% |
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
| Coherus Oncology inc | Named by the company | 85% |
| Beone Medicines Ltd | Named by the company | 85% |
| Cue Biopharma Inc | Named by the company | 85% |
| Rafael Holdings Inc | Named by the company | 85% |
| Bright Minds Biosciences Inc | Named by the company | 85% |
| Fulgent Genetics Inc | Named by the company | 85% |
| Akero Therapeutics Inc | Named by the company | 85% |
| Sagimet Biosciences inc | Named by the company | 85% |
| Intra cellular Therapies Inc | Named by the company | 85% |
| Macrogenics Inc | Named by the company | 85% |
| Mirati | Named by the company | 85% |
| Vincerx Pharma Inc | Named by the company | 85% |
| Marker Therapeutics inc | Named by the company | 85% |
| Carisma Therapeutics Inc | Named by the company | 85% |
| Nuvalent Inc | Named by the company | 85% |
| Clearside Biomedical Inc | Named by the company | 85% |
| Cytokinetics Incorporated | Named by the company | 85% |
| Arcellx Inc | Named by the company | 85% |
| Scinai Immunotherapeutics Ltd | Named by the company | 85% |
| Exscientia Plc | Named by the company | 85% |
| Immunome Inc | Named by the company | 85% |
| Alx Oncology Holdings Inc | Named by the company | 85% |
| Sonnet Biotherapeutics Holdings Inc | Named by the company | 85% |
| Lineage Cell Therapeutics Inc | Named by the company | 85% |
| BGNE | Named by the company | 85% |
| Tempest Therapeutics Inc | Named by the company | 85% |
| Candel Therapeutics Inc | Named by the company | 85% |
| Nurix Therapeutics Inc | Named by the company | 85% |
| Cell Source Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bristol Myers Squibb's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Bristol Myers Squibb's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Bristol myers Squibb Company.
Bristol Myers Squibb's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bristol myers Squibb Company | 130,437 | 1,513,415 | 285,354 |
| Akari Therapeutics Plc | 1,180,445 | - | -4,674,667 |
| Eli Lilly And Company | 1,054,271 | 1,593,316 | 534,224 |
| Johnson and Johnson | 662,243 | 695,518 | 149,411 |
| Beone Medicines Ltd | 543,752 | 510,686 | 54,642 |
| Abbvie Inc | 473,291 | 1,129,579 | 110,807 |
| PEERS TOTAL | 6,796,321 | 891,402 | 108,658 |
Sign in to see all peers for Bristol myers Squibb Company.
Bristol Myers Squibb's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 67.79 % |
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Bristol myers Squibb Company.
Bristol Myers Squibb's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Bristol Myers Squibb's industry classification, broader than the peer set above. Market cap in millions of $.Bristol Myers Squibb ranks #11 of 498 companies by market capitalization in its industry, holding 2.38 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,054,271 | 19.27 % |
| 2 | Johnson and Johnson | 662,243 | 12.10 % |
| 3 | Beone Medicines Ltd | 543,752 | 9.94 % |
| 4 | Abbvie Inc | 473,291 | 8.65 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 11 | Bristol myers Squibb Company | 130,437 | 2.38 % |
Market cap and industry share for the rest of Bristol Myers Squibb's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Bristol Myers Squibb's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 6 | Novartis Ag | 284,237 | 17.58 % |
| 7 | Abbott Laboratories | 175,354 | -24.84 % |
| 8 | Novo Nordisk A | 170,296 | -31.21 % |
| 9 | Pfizer Inc | 163,652 | 20.86 % |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 12.3% |
| 11 | Bristol myers Squibb Company | 130,437 | 44.36 % |
| 12 | Astrazeneca Plc | 1,234 | 12.3% |
| 13 | Gsk Plc | 1,234 | 12.3% |
| 14 | Sanofi | 1,234 | 12.3% |
| 15 | Regeneron Pharmaceuticals Inc | 1,234 | 12.3% |
| 16 | Teva Pharmaceutical Industries Limited | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bristol Myers Squibb's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bristol Myers Squibb's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 70.16 % | 64.89 % (avg) | +5.3 pp |
| Operating Margin | 23.96 % | industry median | +77.6 pp |
| EBITDA Margin | 31.97 % | -7.21 % (avg) | +39.2 pp |
| Capital Intensity (Capex / Revenue) | 2.73 % | 4.92 % (avg) | -2.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Bristol Myers Squibb's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 12.7x | 25.1x | -12.4x |
| EV / EBITDA | 9.7x | 17.3x | -7.6x |
| P/B | 6.0x | 4.5x | +1.5x |
| Return on Equity | 46.65 % | industry aggregate | 29.40 % |
| Return on Invested Capital | 13.42 % | -2.95 % (avg) | 16.37 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bristol Myers Squibb's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 8.59 % | 15.89 % | 62.62 % | 9.09 % | -0.49 % | -2.50 % | 7.32 % | -0.22 % |
| Operating Margin | 22.69 % | 22.62 % | -21.60 % | 15.91 % | 17.96 % | 16.18 % | -15.50 % | 20.75 % |
| Return on Invested Capital | 13.81 % | 7.14 % | -6.06 % | 5.77 % | 7.50 % | 7.07 % | -8.51 % | 11.66 % |
| P/E | 17.0x | 28.1x | - | 19.4x | 25.7x | 13.1x | - | 15.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bristol Myers Squibb's Strategic Group Map
Every company in Bristol Myers Squibb's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Bristol Myers Squibb is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Bristol Myers Squibb's BCG Growth-Share Matrix
Relative market share (vs Bristol Myers Squibb's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Bristol Myers Squibb falls in the Dog quadrant: relative market share of 0.12x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bristol Myers Squibb's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.73 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Bristol Myers Squibb's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Bristol Myers Squibb's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Bristol Myers Squibb's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Bristol Myers Squibb falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bristol Myers Squibb's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 77.6 points above the industry median.
- Return on equity 29.4 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+5.5% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.12x).
Opportunities
- Trades at a lower P/E than the industry average (12.7x vs 25.1x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of tracked competitors (42.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Bristol Myers Squibb's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
Sign in to see all peers for Bristol myers Squibb Company.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bristol Myers Squibb's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| PEERS TOTAL | +9.6 % | -4.7 % |
Sign in to see all peers for Bristol myers Squibb Company.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bristol Myers Squibb's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
Sign in to see all peers for Bristol myers Squibb Company.
Bristol Myers Squibb's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Akari Therapeutics Plc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
Sign in to see all peers for Bristol myers Squibb Company.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bristol Myers Squibb's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bristol myers Squibb Company | 14.02 | 2.65 |
| Akari Therapeutics Plc | - | - |
| Eli Lilly And Company | 39.60 | 13.23 |
| Johnson and Johnson | 31.41 | 6.76 |
| Beone Medicines Ltd | 820.93 | 88.73 |
| Abbvie Inc | 75.49 | 7.35 |
| PEERS AVERAGE | 59.28 | 7.43 |
Sign in to see all peers for Bristol myers Squibb Company.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.